Oforta
FDA Approves Iclusig for Rare Leukemia »
"The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.
"...Oforta
OVERDOSE
High doses of fludarabine phosphate [See INDICATIONS AND USAGE and WARNINGS AND PRECAUTIONS] have been associated with an irreversible central nervous system toxicity characterized by delayed blindness, coma and death. High doses are also associated with severe thrombocytopenia and neutropenia due to bone marrow suppression. There is no known specific antidote for fludarabine phosphate overdosage. Treatment consists of drug discontinuation and supportive therapy. In Study 2, two patients ingested an overdose of 20% to 33% of Oforta™ (fludarabine phosphate tablets) . No serious side effects were reported.
CONTRAINDICATIONS
None
Last reviewed on RxList: 8/5/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Oforta Information
Oforta - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.






